pharmaphorum September 26, 2024
BioAge Labs has completed its upsized initial public offering (IPO), raising $198 million after increasing the number of shares on offer by 40%.
The expansion of the listing reflects the massive investor appetite for companies with assets in the clinic for obesity and takes the on-paper value of the Richmond, California-based company above $600 million. BioAge sold 11 million shares at a price of $18 apiece, well above its earlier estimate of 7.5 million.
The IPO, which should see BioAge start trading on the Nasdaq today under the BIOA symbol, follows a $170 million Series D financing that completed in February and was earmarked for its phase 2 trials programme.
The company is focusing on the development of oral apelin...
Today's Sponsors
Today's Sponsor